Sunny Pharmtech Inc. (6676.TWO)

TWD 21.85

(-0.46%)

Market Cap (In TWD)

3.25 Billion

Revenue (In TWD)

428.82 Million

Net Income (In TWD)

-63.32 Million

Avg. Volume

315.89 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
21.1-38.15
PE
-
EPS
-
Beta Value
-0.05
ISIN
TW0006676000
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Yon-Lian Wu
Employee Count
-
Website
https://www.sunnypharmtech.com
Ipo Date
2022-01-19
Details
Sunny Pharmtech Inc. engages in the research, development, production, and sale of drug substances and products, and active pharmaceutical ingredients in Taiwan and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage. The company was founded in 1994 and is based in Taoyuan, Taiwan.